<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04550247</url>
  </required_header>
  <id_info>
    <org_study_id>CA209-7HU</org_study_id>
    <nct_id>NCT04550247</nct_id>
  </id_info>
  <brief_title>A Prospective Non-Interventional Study in Participants Receiving Nivolumab in Adjuvant Setting for Resected Melanoma in Real-World Conditions in France</brief_title>
  <acronym>AdjuMel</acronym>
  <official_title>A National, Prospective, Non- Interventional Study (NIS) in Patients Receiving Adjuvant Nivolumab Therapy for Resected Melanoma and Subsequent Treatments in Case of Relapse</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an observational prospective study to estimate in real world conditions the&#xD;
      effectiveness, the safety profile and the pattern of use of adjuvant nivolumab in adults&#xD;
      participants with stage III/IV resected melanoma, and subsequent treatments administered in&#xD;
      case of relapse.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 2, 2020</start_date>
  <completion_date type="Anticipated">March 15, 2027</completion_date>
  <primary_completion_date type="Anticipated">March 15, 2027</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Relapse-Free Survival (RFS)</measure>
    <time_frame>up to 60 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Distant Metastasis-Free Survival (DMFS)</measure>
    <time_frame>Up to 60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to 60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse-Free Survival 2 (RFS2)</measure>
    <time_frame>Up to 60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>Up to 60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of health related quality of life</measure>
    <time_frame>Up to 60 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of sociodemographic characteristics</measure>
    <time_frame>Up to 60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of clinical characteristics</measure>
    <time_frame>Up to 60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of nivolumab therapy: number of infusions</measure>
    <time_frame>Up to 60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of nivolumab therapy: number of dosing</measure>
    <time_frame>Up to 60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Nivolumab: pattern of use</measure>
    <time_frame>Up to 60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characteristics of nivolumab adjuvant safety profile: incidence</measure>
    <time_frame>Up to 60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characteristics of nivolumab adjuvant safety profile: grade</measure>
    <time_frame>Up to 60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characteristics of nivolumab adjuvant safety profile: type</measure>
    <time_frame>Up to 60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characteristics of nivolumab adjuvant safety profile: time to onset of select AEs</measure>
    <time_frame>Up to 60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characteristics of nivolumab adjuvant safety profile: time to onset of other immune- related AEs</measure>
    <time_frame>Up to 60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characteristics of nivolumab adjuvant safety profile: time to resolution of select AEs</measure>
    <time_frame>Up to 60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characteristics of nivolumab adjuvant safety profile: time to resolution of other immune-related AEs</measure>
    <time_frame>Up to 60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Describe the use of subsequent therapies after relapse following adjuvant nivolumab</measure>
    <time_frame>Up to 60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimate the effectiveness of systemic therapies administered after relapse following adjuvant nivolumab, in terms of time and duration of response</measure>
    <time_frame>Up to 60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimate the effectiveness of systemic therapies administered after relapse following adjuvant nivolumab, in terms of overall response rate</measure>
    <time_frame>Up to 60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety profile of systemic therapies administered after relapse in terms of severe adverse events incidence, type, management and outcome</measure>
    <time_frame>Up to 60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimate the effectiveness of subsequents treatments administered after relapse in terms of PFS</measure>
    <time_frame>Up to 60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimate the effectiveness of subsequents treatments administered after relapse in terms of RFS2</measure>
    <time_frame>Up to 60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimate the effectiveness of subsequents treatments administered after relapse in terms of OS</measure>
    <time_frame>Up to 60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characteristics of nivolumab adjuvant safety profile: management</measure>
    <time_frame>Up to 60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characteristics of nivolumab adjuvant safety profile: outcome</measure>
    <time_frame>Up to 60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety profile of systemic therapies administered after relapse in terms of severe adverse events: Incidence</measure>
    <time_frame>Up to 60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety profile of systemic therapies administered after relapse in terms of severe adverse events: Type</measure>
    <time_frame>Up to 60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety profile of systemic therapies administered after relapse in terms of severe adverse events: Management</measure>
    <time_frame>Up to 60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety profile of systemic therapies administered after relapse in terms of severe adverse events: Outcome</measure>
    <time_frame>Up to 60 months</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">350</enrollment>
  <condition>Melanoma</condition>
  <arm_group>
    <arm_group_label>Nivolumab treatment</arm_group_label>
    <description>Administered according to the market authorization in France</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        The study will collect data primarily from hospital based dermatology and oncology care&#xD;
        facilities&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        For more information regarding Bristol-Myers Squibb Clinical Trial participation,please&#xD;
        visit www.BMSStudyConnect.com.&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants with a primary diagnosis of melanoma with involvement of lymph nodes or&#xD;
             metastatic disease who have undergone complete resection and have no evidence of&#xD;
             disease&#xD;
&#xD;
          -  Decision to treat with adjuvant nivolumab therapy has already been taken&#xD;
&#xD;
          -  Participants who provide oral informed consent to participate in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any participant with a current diagnosis of persisting advanced melanoma&#xD;
&#xD;
          -  Participants with a current primary diagnosis of a cancer other than advanced&#xD;
             melanoma, ie, a cancer other than melanoma that requires systemic or other treatment&#xD;
             or has not been treated curatively (as per discretion of the investigator)&#xD;
&#xD;
          -  Any participants currently enrolled in an interventional clinical trial for his/her&#xD;
             melanoma treatment (note: patients who have completed their participation in an&#xD;
             interventional trial or who are no longer receiving the study drug and are only&#xD;
             followed up for OS/RFS can be enrolled. In case of a blinded study, the treatment arm&#xD;
             needs to be known).&#xD;
&#xD;
          -  Pregnant women&#xD;
&#xD;
          -  Person under guardianship&#xD;
&#xD;
        Other protocol defined inclusion/exclusion criteria apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Recruiting sites have contact information. Please contact the sites directly. If there is no contact information,</last_name>
    <phone>please email:</phone>
    <email>Clinical.Trials@bms.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>First line of the email MUST contain NCT# and Site #.</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>HÃ´pital Saint Louis</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 9, 2020</study_first_submitted>
  <study_first_submitted_qc>September 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 16, 2020</study_first_posted>
  <last_update_submitted>September 9, 2020</last_update_submitted>
  <last_update_submitted_qc>September 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

